Laidlaw Believes Cara Therapeutics (NASDAQ: CARA) Won’t Stop Here

By Jason Carr

In a report released today, James Molloy from Laidlaw reiterated a Buy rating on Cara Therapeutics (NASDAQ: CARA), with a price target of $30. The company’s shares closed yesterday at $25.51, close to its 52-week high of $28.50.

Molloy has an average return of 50.7% when recommending Cara Therapeutics.

According to TipRanks.com, Molloy is ranked #3010 out of 4600 analysts.

Currently, the analyst consensus on Cara Therapeutics is Strong Buy and the average price target is $25.71, representing a 0.8% upside.

In a report issued on June 21, Needham also reiterated a Buy rating on the stock with a $23 price target.

The company has a one year high of $28.50 and a one year low of $4.75. Currently, Cara Therapeutics has an average volume of 2.13M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CARA Therapeutics, Inc. is a clinical-stage company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E.

  • Benjamín Joel Fleet

    Looks like somebody missed the memo. CARA tanked in after-hours trading.